Vaccine adjuvants: scientific challenges and strategic initiatives.
about
Vaccines: from empirical development to rational designToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesApplication of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative VaccinesNear-infrared laser adjuvant for influenza vaccineEffect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.Laser vaccine adjuvants. History, progress, and potentialIncreased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.Chemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biologyImmune enhancement by novel vaccine adjuvants in autoimmune-prone NZB/W F1 mice: relative efficacy and safety.Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccinesHighly effective generic adjuvant systems for orphan or poverty-related vaccinesIdentification of immunodominant antigens of Chlamydia trachomatis using proteome microarraysSelection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccineA TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogensHuman prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.Role of adjuvants in modeling the immune response.Topical and mucosal liposomes for vaccine delivery.Toll-like receptor modulators: a patent review (2006-2010).Influenza virosomes as a vaccine adjuvant and carrier system.Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.Outer membrane vesicles: an attractive candidate for pertussis vaccines.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Liposomes containing glucosyl ceramide specifically bind T4 bacteriophage: a self-assembling nanocarrier formulation.Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein.
P2860
Q21089599-8FF5DC63-C267-4216-B47C-3A69947CC54CQ24624348-7059E0DC-D0C7-4EA0-A419-12A7E0A761BDQ26783957-77952D4E-0D60-4767-8274-EE8F26CADC9DQ28536886-3BF4D8A9-ABDA-4BB3-AA20-3CD4269789B9Q30401304-1C885078-8446-462A-B6FD-A168CD6A16DEQ30413501-B1B1FAB9-7434-4C10-BEDD-8DC9772CB088Q33648677-67B347F8-68E0-4757-A92A-816E9ADD8360Q33714195-30070CAA-8B47-49D9-8249-D3F4B8C81F2CQ33930469-5C94787C-5CEC-4E8D-81D3-7F659B6BB59DQ34056902-7191F5E2-629E-40D7-8B88-EA9E64814DCFQ34067461-0988727C-1A39-4412-8A79-57B548115E1CQ34290717-A175001C-0C67-4908-A961-0ACDB8B36B71Q34307955-0F322CE1-8E77-4446-B17A-E33360B3D435Q34623193-DE85ECAE-8CE2-459E-899E-6A8C0AD48948Q34869353-102EFC59-0BFB-49EF-851D-68BCC04D6E58Q35042764-82CF27DF-028A-44D4-9238-DF7E6409D7BFQ35166960-B86678A2-FF8A-400F-95CA-E7EB843D27B2Q36500269-54CF5CBF-210D-4FBB-A4C2-64CE42D7BE81Q37371036-C4AC5655-C152-488A-A8B0-AD497F4E7C48Q37662675-4D46AFD6-AB9A-4EAF-B9E8-7F114B139179Q37803320-7162DDB0-D7EA-4DA5-BF6A-0A61D2A5503EQ37848296-4BA5246A-D122-4E19-B75F-FEC5719C557AQ37853197-18455621-E2EA-425A-B33F-50638E714066Q37867100-D0C27461-0BB3-4279-8C33-DD0113F56DA6Q38032881-83D4CAE8-28A5-478E-9098-B72FB14AB304Q38066148-A9E79F23-47A8-47F3-8106-E0CA090C8CF1Q40410058-31534F75-CA66-4F35-863D-0BF5830882ECQ40752357-B502BE96-D9B9-4534-8420-14437D62795FQ46781197-9CF272BB-F952-4739-9DAC-DF42595BB1BBQ55472927-C53D8FB5-2225-4740-BC63-9FB5751CAE7E
P2860
Vaccine adjuvants: scientific challenges and strategic initiatives.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccine adjuvants: scientific challenges and strategic initiatives.
@en
Vaccine adjuvants: scientific challenges and strategic initiatives.
@nl
type
label
Vaccine adjuvants: scientific challenges and strategic initiatives.
@en
Vaccine adjuvants: scientific challenges and strategic initiatives.
@nl
prefLabel
Vaccine adjuvants: scientific challenges and strategic initiatives.
@en
Vaccine adjuvants: scientific challenges and strategic initiatives.
@nl
P2093
P2860
P356
P1476
Vaccine adjuvants: scientific challenges and strategic initiatives.
@en
P2093
Ali M Harandi
Gwyn Davies
Ole F Olesen
P2860
P304
P356
10.1586/14760584.8.3.293
P577
2009-03-01T00:00:00Z